Jinxin Fertility Group Limited (JXR) disclosed a fresh on-market repurchase of 2.27 million ordinary shares on 6 October 2026, paying a volume-weighted average price of HK$2.2314 per share and spending a total of HK$5.03 million. The purchase price ranged between HK$2.19 and HK$2.23.

Following the transaction, JXR’s issued share capital (excluding treasury shares) fell 0.08 percentage points to 2.67079 billion shares, while treasury shares increased to 34.25 million. Total issued shares remained unchanged at 2.70504 billion as the repurchased shares were transferred to treasury stock rather than cancelled.

The latest buyback forms part of the company’s HK$262.51 million share-repurchase mandate approved on 25 June 2026. To date, JXR has utilised 46.80 million shares, equivalent to 1.78 % of the shares outstanding on the mandate date, leaving roughly 215.72 million shares—about 82 % of the mandate—still available for future repurchases.

In addition, 92.47 million shares (3.46 % of current issued shares excluding treasury stock) that were repurchased between March and August 2026 remain in the process of cancellation. The aggregate of these pending cancellations and treasury shares now totals 126.72 million shares.

Pursuant to Hong Kong Stock Exchange rules, JXR is restricted from issuing new shares or disposing of treasury shares until 5 November 2026, 30 days after the most recent buyback.

The company confirmed that all repurchases complied with the HKEX Main Board Listing Rules and that no material changes have been made to the repurchase mandate’s explanatory statement.